139 related articles for article (PubMed ID: 8869469)
1. Induction of immune tolerance, the future of the Registry.
Ewing NP
Vox Sang; 1996; 70 Suppl 1():47-51. PubMed ID: 8869469
[TBL] [Abstract][Full Text] [Related]
2. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.
Mariani G; Kroner B;
Haematologica; 2001 Nov; 86(11):1186-93. PubMed ID: 11694405
[TBL] [Abstract][Full Text] [Related]
3. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy.
Dimichele D
Haemophilia; 2009 Jan; 15(1):320-8. PubMed ID: 18976249
[TBL] [Abstract][Full Text] [Related]
4. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.
DiMichele D; Kroner B;
Haematologica; 2000 Oct; 85(10 Suppl):40-2; discussion 42-4. PubMed ID: 11187869
[TBL] [Abstract][Full Text] [Related]
5. The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?
Ettingshausen CE; Kreuz W
Haemophilia; 2013 Jan; 19 Suppl 1():12-7. PubMed ID: 23278995
[TBL] [Abstract][Full Text] [Related]
6. Immune tolerance: critical issues of factor dose, purity and treatment complications.
DiMichele DM
Haemophilia; 2006 Dec; 12 Suppl 6():81-5; discussion 85-6. PubMed ID: 17123399
[TBL] [Abstract][Full Text] [Related]
7. New protocol for immune tolerance induction in acquired hemophilia.
Nemes L; Pitlik E
Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
[TBL] [Abstract][Full Text] [Related]
8. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
[TBL] [Abstract][Full Text] [Related]
9. Novel therapies for immune tolerance in haemophilia A.
Collins PW
Haemophilia; 2006 Dec; 12 Suppl 6():94-100; discussion 100-1. PubMed ID: 17123401
[TBL] [Abstract][Full Text] [Related]
10. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
11. Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee.
Mariani G; Ghirardini A; Bellocco R
Thromb Haemost; 1994 Jul; 72(1):155-8. PubMed ID: 7974364
[TBL] [Abstract][Full Text] [Related]
12. Factor VIII inhibitors. Immune tolerance induction: is it cost effective? We know too little.
Aledort LM
Semin Thromb Hemost; 2000; 26(2):189-93. PubMed ID: 10919412
[TBL] [Abstract][Full Text] [Related]
13. Hemophilia treatment. Immune tolerance induction: prospective clinical trials.
Hay CR
Haematologica; 2000 Oct; 85(10 Suppl):52-5; discussion 55-6. PubMed ID: 11187872
[TBL] [Abstract][Full Text] [Related]
14. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.
van Helden PM; van den Berg HM; Gouw SC; Kaijen PH; Zuurveld MG; Mauser-Bunschoten EP; Aalberse RC; Vidarsson G; Voorberg J
Br J Haematol; 2008 Aug; 142(4):644-52. PubMed ID: 18510679
[TBL] [Abstract][Full Text] [Related]
15. The treatment of factor VIII inhibitors--a general overview.
White GC; Roberts HR
Vox Sang; 1996; 70 Suppl 1():19-23. PubMed ID: 8869464
[TBL] [Abstract][Full Text] [Related]
16. The role of VWF for the success of immune tolerance induction.
Kreuz W
Thromb Res; 2008; 122 Suppl 2():S7-S12. PubMed ID: 18549910
[TBL] [Abstract][Full Text] [Related]
17. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
Auerswald G; Spranger T; Brackmann HH
Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
[TBL] [Abstract][Full Text] [Related]
18. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
[TBL] [Abstract][Full Text] [Related]
19. Immunological aspects of inhibitor development.
Reding MT
Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
[TBL] [Abstract][Full Text] [Related]
20. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.
Unuvar A; Kavakli K; Baytan B; Kazanci E; Sayli T; Oren H; Celkan T; Gursel T
Haemophilia; 2008 Mar; 14(2):315-22. PubMed ID: 18081830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
